DOCSLIB.ORG

Type Title Here

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Type Title Here From Pig Viruses to Insect Vectors and New Adjuvants Meg Fisher, MD and Paul Offit, MD Disclosures Meg Fisher has no disclosures and will be mentioning off label uses of vaccines. Paul Offit has played a major role in the development of rotavirus vaccine Objectives Counsel parents regarding the risks and benefits of rotavirus vaccines Discuss the newest techniques and adjuvants used in producing vaccines Advise families regarding the newest ACIP recommendations The Rotavirus Vaccine Saga Rotashield and intussusception RotaTeq, Rotarix and porcine circoviruses Post-licensure studies Human Papillomaviruses Over 100 types Specialized for epithelia Not cytotoxic, viral genes promote replication and delay differentiation, leads to proliferative lesions (warts) Genital warts Genital epithelium and mucosa Warts HPV 6 and 11 No cancers recognized High-risk genital Genital epithelium and mucosa Flat warts or subclinical HPV 16, 18, 31, 45 Cervical dysplasia and cancer Epidemiology Spread person to person by close contact Asymptomatic people can transmit Anogenital – over 40 types, sexual spread Over 40% of adolescents infected Regular condom use does decrease risk Incubation unknown, probably months to yrs HPV Vaccines Virus-like particles genetically engineered Capsid proteins form empty virus shell Well tolerated and immunogenic Three dose series: 0, 1, 6 months Ongoing efficacy studies Methods Recombinant technology: genetic engineering Gardasil: Saccharomyces cerevisiae produces the capsid proteins Cervarix: Baculovirus vector in Trichoplusia ni insect cells produces the capsid proteins Capsid proteins self-assemble into virus-like particles (VLP) Adjuvants Gardasil: aluminum-containing adjuvant (Amorphous Aluminum Hydroxyphosphate Sulfate) Cervarix: AS04: 3-O-desacyl-4’- monophosphoryl lipid A (MPL) adsorbed on to aluminum (as hydroxide salt) Preservatives, Additives and Residuals Thimerosal, phenol, 2-phenoxyethanol Sugars, amino acids, proteins (gelatin, albumen, cow derived stuff) Antibiotics, formaldehyde, cellular products (egg, yeast) Gardasil (Merck) Quadrivalent types 6, 11, 16, 18 Immunogenic in girls and boys 100% effective against persisting infection Effective in preventing genital warts Licensed 2006 for girls, 2009 for boys Cervarix (GSK) Types 16 and 18 Well tolerated, immunogenic and effective Not studied in boys Licensed 2009 for girls age 10 through 25 Recommendation: females as for Gardasil Novel production, novel adjuvant Other Cool Methods Hepatitis B: Saccharomyces cerevisiae produces surface antigen Conjugates: antigen is attached to a protein to cause a T-cell dependent response Influenza cold adapted virus Conjugate Vaccines T-cell dependent immune response Immune memory, booster effect Long-term protection Reduction of carriage Herd immunity Courtesy of the Centers for Disease Control and Prevention Courtesy of the Centers for Disease Control and Prevention Courtesy of the Centers for Disease Control and Prevention Menactra, Menveo Meningococcal serotypes A, C, Y, W-135 Menactra: conjugated to diphtheria toxoid Licensed in January 2005 Menveo: conjugated to diphtheria CRM197 Licensed in February 2010 Recommendations Adolescents age 11-12 yr (pre-teen visit) Catch up all other adolescents Incoming college freshmen in dorms High risk: microbiologists, travelers, military recruits, complement deficiency, asplenia 2010 ACIP Highest risk patients need 2 doses, 2 months apart and boosters every 3-5 years Adolescent booster at age 16 years If immunized at age 13-15, consider another dose in 5 years (up to age 21) These are not yet official Whooping Cough Disease most severe under 6 months Coughing illness: 100 day cough Teens and young adults Paroxysmal, post-tussive vomiting Duration of cough 6 to 10 weeks Outbreaks in CA, OH, and PA Pertussis Vaccines DTP: no longer used in US DTaP: for the primary series Tdap: for teens and adults, licensed in spring of 2005, should have altered epidemiology and protect infants Tdap: Boostrix, Adacel Tetanus, diphtheria, pertussis booster For teens and adults Licensed for ages 10 to 64 years: gaps for youngest and oldest Uptake to date in adults 5.9%; healthcare workers only 13.9% 2010 ACIP Tdap dose for under-immunized children ages 7 to 10 years Tdap dose for those over 64 years These are off label uses Still waiting for data on giving a second Tdap National Vaccine Injury Compensation Program Established by National Childhood Vaccine Injury Act No fault compensation program http://www.hrsa.gov/vaccinecompensation/ Report suspected adverse events to VAERS Smiling is a contagious condition!.
Load more

Recommended publications
  • Paul Offit: Claiming the High Gr Ound I N the Vaccine C Ontroversy
    PaUl oFFIt: CLAIMInG tHe HIGH GR oUnD I n tHe VaCCINE C ontRoVeRsY BY B rian G. Connell Y aul aul s my my a ourtesy c hen Paul Offit (Res ’80) was a resi- dent in the emergency department at / photo WChildren’s Hospital of Pittsburgh in RRIS the late 1970s, he had a patient—a 9-month- rank ha old infant—who died of rotavirus. Offit was f shocked to realize that this common intestinal infection still killed children in the United illustration States. A leading cause of severe diarrhea in Offit is co-inventor of the rotavirus vaccine RotaTeq, which was recommended for routine infants and young children, rotavirus contrib- immunizations in infants by the World Health Organization. utes to more than half a million deaths world- wide each year. have advanced the belief that there’s a link Offit, who has testified in congressional Some three decades later, in 2009, between vaccines and autism. The suspect hearings on vaccine safety, says the conse- RotaTeq— a vaccine for rotavirus—was recom- vaccines change, but the story remains the quences of skipping vaccines are not theo- mended by the World Health Organization to same: Citing anecdotes or data taken out of retical. He points to the pertussis outbreak in protect against the deadly infection. RotaTeq context, activist groups accuse physicians and California this year, which killed 10 infants is the fruit of 25 years of labor for Offit, the pharmaceutical companies of concealing what and infected 9,000 people. “We’re past the vaccine’s coinventor who is now a renowned they believe are harmful effects associated with tipping point,” he says.
    [Show full text]
  • Myocarditis and Mrna Vaccines
    Updated June 28, 2021 DOH 348-828 Information for Clinical Staff: Myocarditis and mRNA Vaccines This document helps clinicians understand myocarditis and its probable link to some COVID-19 vaccines. It provides talking points clinicians can use when discussing the benefits and risks of these vaccines with their patients and offers guidance on what to do if they have a patient who presents with myocarditis following vaccination. Myocarditis information What are myocarditis and pericarditis? • Myocarditis is an inflammation of the heart muscle. • Pericarditis is an inflammation of the heart muscle covering. • The body’s immune system can cause inflammation often in response to an infection. The body’s immune system can cause inflammation after other things as well. What is the connection to COVID-19 vaccination? • A CDC safety panel has determined there is a “probable association” between myocarditis and pericarditis and the mRNA COVID-19 vaccines, made by Moderna and Pfizer-BioNTech, in some vaccine recipients. • Reports of myocarditis and pericarditis after vaccination are rare. • Cases have mostly occurred in adolescents and young adults under the age of 30 years and mostly in males. • Most patients who developed myocarditis after vaccination responded well to rest and minimal treatment. Talking Points for Clinicians The risk of myocarditis is low, especially compared to the strong benefits of vaccination. • Hundreds of millions of vaccine doses have safely been given to people in the U.S. To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email [email protected].
    [Show full text]
  • Presentation of Stanley Plotkin
    Vaccine Safety by Stanley A. Plotkin Advac Alumni 2019.pptx Sept. 22, 2019 Plotkin, Pediatrics, 2019; 143 2 (Cont.) 3 Vaccine Safety Library Topics May 2019 Heather Monk Bodenstab, PharmD, Paul Offit, MD, Frank DeStefano, MD • Adjuvants Other than Aluminum in Vaccines o Squalene (MF59, AS03, AF03) o Monophosphoryl lipid A (MPL), Saponin (QS21), and Related Adjuvant Systems (AS01, AS02, AS04) o CpG • Aluminum in Vaccines • Diabetes and Vaccines o Type-1 Diabetes o Gestational Diabetes • DNA and Vaccines • Egg Allergy and Vaccines o Influenza Vaccine o Measles-Containing Vaccine o Yellow Fever Vaccine • Guillain-Barre Syndrome (GBS) and Vaccines 4 Vaccine Safety Library Topics (cont.) May 2019 Heather Monk Bodenstab, PharmD, Paul Offit, MD, Frank DeStefano, MD • Human Papillomavirus (HPV) Vaccine Safety Concerns o HPV Vaccine and Chronic Fatigue Syndrome (CFS)/Systemic Exertion Intolerance Disease (SEID) o HPV Vaccine and Multiple Sclerosis/Central Demyelinating Disease o HPV Vaccine and Postural Orthostatic Tachycardia Syndrome (POTS) o HPV Vaccine and Primary Ovarian Insufficiency o HPV Vaccine and Promiscuity o HPV Vaccine and Venous Thromboembolism (VTE) • MMR and Autism • Multiple Sclerosis/Central Demyelinating Disease and Vaccines o Hepatitis B o Flu Vaccine • Pertussis Vaccine and Neurologic Complications • Pregnancy and Vaccines o HPV Vaccine and Pregnancy o Influenza Vaccine and Pregnancy o Pertussis-containing Vaccines and Pregnancy • Sudden-infant death syndrome (SIDS) and Vaccines • Thimerosal and Autism • Too Many, Too Soon • Vaccine Ingredients o Formaldehyde o Gelatin o Polysorbate 80 • Yeast and Vaccines 5 Package Insert for MMR Risks of a Vaccine Reaction . Soreness, redness, or rash where the shot is given and rash all over the body can happen after MMR vaccine.
    [Show full text]
  • COVID-19 Vaccine and CMT – Q & A
    COVID-19 Vaccine and CMT – Q & A Disclaimer: Nothing shared on these pages should be construed or is intended to be used for medical diagnosis or treatment. It should not be used in place of the advice of your physician or other qualified health care provider. Should you have any emergency questions or concerns, please contact your physician or health care provider immediately. Always consult with your physician or other health care provider to gain clarification regarding any health care related questions. This content was sourced from the CDC, the CMTA Scientific Advisory Board, the MDA and the NY Times. What are the side effects of the COVID vaccine? Will they affect my CMT? The known side effects of current and likely-to-be authorized COVID-19 vaccines are similar to those of the annual influenza vaccine. These include symptoms such as: muscle soreness at the injection site, fever, tiredness, body aches and headache. It’s important to note that at this time we do not know whether or not the COVID-19 vaccine will have a different or more serious set of side effects for CMT patients. You should talk to your doctor about the possibility of more serious side effects of a COVID-19 vaccine for you. What impacts will the vaccine have on possible future gene therapy treatments or medications? Whether the vaccine will have an adverse impact on any course of treatment that you or your loved one may be taking is something that you will want to consult with your clinician about directly. Upon the FDA authorization of the Pfizer/BioNTech vaccine, the FDA did not name any contraindications pertaining to genetic therapies or other medications particularly important to the CMT community.
    [Show full text]
  • Immunization Pearls in This Issue
    DCIC Pearls Newsletter Print Immunization Pearls In this issue Membership meeting summary Immunizations in the news Stay Sharp- Educational Opportunities General Membership Meeting Summary Feb. 21, 2017 Jenny Kind (UHS) update on Mening B --most students immunized in fall did not receive 2nd dose at provider as recommended. Sally Zirbel Donish (MMSD)-partnership with DCIC, PHMDC and State grant made clinics possible Elizabeth Bourke (Deerfield School Nurse)--challenges of rural health and immunization access, particularly with 6th grade Tdap completion. Struggle with required Tdap coverage by exclusion deadline Dr. Conway-raised concerns of whether the school clinics sustainable. Public Health Prevention Fund at risk with serious impact on immunization programs and others as a result. Stay tuned.... Diane McHugh, PHMDC-- Coalition Engagement: School Based Clinics For complete meeting minutes and slides, see the DCIC website Save the Dates! DCIC Membership Meetings continue at the Madison Water Utility at 119 E. Olin Ave, Madison. Tuesdays from 12-1:30 on the following dates for 2017 DCIC Pearls Newsletter.html[6/15/2017 9:36:08 AM] DCIC Pearls Newsletter May 16 August 15 November 14 Immunization Update 2017 Wednesday April 5, 2017 5:00-6:00 pm Dinner 6:00-8:00 Presentation by Dr. Paul Hunter, "Adult Vaccine Update", followed by panel discussion of "Vaccine Hesitancy, from Babies to Boomers". American Family Insurance Education and Training Center 6000 American Pkwy Madison WI (between Sun Prairie and Madison) For health care staff who administer vaccines or facilitate administration. Registration has begun, seating is limited. Register soon. Information is posted on DCIC website.
    [Show full text]
  • Congressional Record—House H5074
    H5074 CONGRESSIONAL RECORD — HOUSE June 23, 2005 As Thomas Jefferson once said, MERCURY AND AUTISM them while at the same time changing Whenever people are well informed, The SPEAKER pro tempore. Under a the Vaccine Injury Compensation Fund they can be trusted with their own gov- previous order of the House, the gen- in a way that will protect these fami- ernment. tleman from Indiana (Mr. BURTON) is lies and help those who have been dam- Maintaining our commitment to pub- recognized for 5 minutes. aged, but so far we have gotten abso- lic broadcasting will help keep the very Mr. BURTON of Indiana. Mr. Speak- lutely nowhere with them; and it is people who elect us well informed, and er, I have been down here a lot talking something I think we need to continue in doing so, help to promote the integ- about autism over the years and my to work on. rity and proper functioning of this very committee had many hearings on the Just recently, there was an article body itself. issue of autism. My grandson became that was published in a magazine I nor- I applaud the Members of this body autistic after receiving 9 shots in one mally do not read. It is called Rolling who rose to the defense of public broad- day, 7 of which contained mercury, in a Stone, but this article was brought to casting earlier today by voting to re- product called thimerosal. And he is my attention, and I think everybody in store funding to a cherished American doing better but it has been a very dif- this body ought to read that article.
    [Show full text]
  • Communicating with the Vaccine Hesitant Client
    Communicating with the Vaccine Hesitant Client Dr. J. Paul Carson, MD, FACP Objectives . Summarize the public health impact of vaccines in the U.S. Discuss root causes of vaccine hesitancy and identify appropriate responses utilizing scientific-based evidence to improve public confidence in vaccine safety and efficacy • Emphasize credible sources of vaccine information 2 Communicating With the Vaccine Hesitant Client Paul J Carson, MD, FACP Overview - Goals Review the main concerns for vaccine hesitancy and their historical origins Review the processes and evidence that assure vaccine safety and necessity Discuss what providers can do in the medical encounter to improve vaccine acceptance © 2013 Template and icons provided by The Advisory Board Company. Overview - Goals Review the main concerns for vaccine hesitancy and their historical origins Review the processes and evidence that assure vaccine safety and necessity Discuss what providers can do in the medical encounter to improve vaccine acceptance © 2013 Template and icons provided by The Advisory Board Company. Ten Greatest Public Health Achievements in the U.S: 1900–1999* Vaccination Motor-vehicle safety Safer workplaces Control of infectious diseases Decline in deaths from coronary heart disease and stroke Safer and healthier foods Healthier mothers and babies Family planning Fluoridation of drinking water Recognition of tobacco use as a health hazard *Topics are not ranked by order of importance. Centers for Disease Control and Prevention. MMWR. 1999;48:241–243. © 2013 Template and icons provided by The Advisory Board Company. History of the Anti-Vaccine Movement What are the Main Concerns? Birth of the Modern Anti-Vaccine Movement • Lea Thompson • Barbara Loe Fisher • April 19, 1982 © 2013 Template and icons provided by The Advisory Board Company.
    [Show full text]
  • Accelerating HPV Vaccine Compliance with the Usage of Mylvhn Patient Portal
    Lehigh Valley Health Network LVHN Scholarly Works Department of Pediatrics Accelerating HPV Vaccine Compliance with the Usage of MyLVHN Patient Portal. Kimberly M. Rarick DO PGY-3 Lehigh Valley Health Network, [email protected] Matthew altS z MD Lehigh Valley Health Network, [email protected] Follow this and additional works at: http://scholarlyworks.lvhn.org/pediatrics Part of the Pediatrics Commons Published In/Presented At Rarick, K. M., Saltz, M. (2017, April 27). Accelerating HPV Vaccine Compliance with the Usage of MyLVHN Patient Portal. Poster Presented at: 2017 Annual POMA Convention, King of Prussa, PA. This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact [email protected]. Accelerating HPV Vaccine Compliance with the Usage of MyLVHN Patient Portal KM Rarick, DO and M Saltz, MD Department of Pediatrics, Lehigh Valley Health Network, Allentown, Pennsylvania INTRODUCTION METHODS RESULTS • Patients 12 to 16 years of age who had previously declined the HPV vaccine were Of the 60 eligible patients aged HHPVPV Va cVaccinationcination Rates Aft eRatesr MyLVH NAfter Implem MyLVHNentation considered eligible for this study. 12-16 years of age, 26 of them Implementation HPV vaccine compliance has been a topic of controversy within many pediatric • Study took place at one LVHN pediatric office, which consisted of six pediatricians, already had or were agreeable to offices across the country. Majority of parents have concerns regarding from October to November of 2016 sign up for MyLVHN.
    [Show full text]
  • Antivaccinationists Absurdly Misusing Dr. Paul Offit's
    Expert Commentary Series Ignoring Context and a Lack of Common Sense: Antivaccinationists Absurdly Misusing Dr. Paul Offit’s “each infant would have the theoretical capacity to respond to about 10,000 vaccines at any one time” By Joel A. Harrison, PhD, MPH March 18, 2016 A recurrent concern among parents is that the mounting number of vaccines now administered to babies is a major challenge to the infantile immune system. Leading advocate of childhood immunizations, Dr. Paul Offit, has sought on numerous occasions to reassure parents by emphasizing how robust and effective babies’ immune systems are at responding to the daily threats from the enormous number of bacteria and viruses they are exposed to. He has illustrated this by showing how - in theory - a baby's immune system could cope with the number of epitopes (parts of a microbe recognized by our immune system) represented by 10,000 vaccines at one time. While 10,000 seems like a lot, as Dr. Offit explains, even this number is small compared to the capacity of our immune system and, yet, it is exponentially greater than the epitopes represented by all the vaccines given to children. Well-organized, well-funded groups have sprung up trying to persuade parents of the alleged dangers of vaccines. Their arguments are mistaken, confused, lack scientific rationale and logical cohesion. There is one claim, based on one statement/sentence made by Dr. Paul Offit, repeated umpteen times all over the blogosphere, that I think encapsulates their flawed thinking. This claim takes one sentence out of context, ignoring the entire lead in to it.
    [Show full text]
  • Vaccines and Related Biological Products Advisory Committee 154Th Meeting
    Food and Drug Administration Center for Biologics Evaluation and Research Vaccines and Related Biological Products Advisory Committee 154th Meeting November 8, 2018 FDA White Oak Campus – Great Room – Salon C Silver Spring, Maryland 20903 MEMBERS Chair David Greenberg, M.D. ***+ Kathryn Edwards, M.D. + Expertise: Industry Representative Expertise: Pediatric Infectious Diseases Term: 02/01/2016 – 01/31/2020 Term: 02/01/2015 – 01/31/2019 Associate Vice President Sarah H. Sell and Cornelius Vanderbilt Regional Medical Head, North America Chair in Pediatrics Sanofi Pasteur Division of Pediatric Infectious Diseases Swiftwater, PA 18370 Vanderbilt University School of Medicine Monroe Carell, Jr. Children’s Hospital at Vanderbilt Holly Janes, Ph.D. Nashville, TN 37232 Expertise: Biostatistics Term: 06/10/2016 – 01/31/2020 Hana El Sahly, M.D. Associate Member Expertise: Vaccines, Infectious Diseases Fred Hutchinson Cancer Research Center Term: 06/10/2016 – 01/31/2020 Vaccine and Infectious Disease Division Associate Professor Division of Public Health Sciences Department of Molecular Virology and Seattle, WA 98109 Microbiology Department of Medicine Michael Kurilla, M.D., Ph.D. + Section of Infectious Diseases Expertise: Infectious Diseases, Pathology Baylor College of Medicine Term: 01/31/2018 – 01/31/2021 Houston, TX 77030 Director, Division of Clinical Innovation National Center for Advancing Translation Leonard Friedland, M.D. Sciences Expertise: Alternate Industry Representative National Institutes of Health Term: 02/01/2016 – 01/31/2020 Bethesda, MD 20852 Vice President Scientific Affairs and Public Health, Vaccines GlaxoSmithKline Philadelphia, PA 19112 **Consumer Representative ***Industry Representative + Not Attending ^ Acting Chair Page 1 of 5 Food and Drug Administration Center for Biologics Evaluation and Research Vaccines and Related Biological Products Advisory Committee 154th Meeting November 8, 2018 FDA White Oak Campus – Great Room – Salon C Silver Spring, Maryland 20903 MEMBERS (Cont’d) Myron Levine, M.D., D.T.P.H., F.A.A.P Arnold Monto, M.D.
    [Show full text]
  • Vaccine Hesitancy)
    Promoting Vaccine Confidence (A New Approach to Vaccine Hesitancy) Michigan Physician Peer Education Project On Immunizations October, 2018 Housekeeping • Dr. Mercatante has no disclosures to make • Please complete your pretest Objectives • Vaccine hesitancy • Answering the tough questions • Common myths and misconceptions about vaccines • Example of vaccine hesitancy-HPV vaccine Some slides throughout the presentation are courtesy of the CDC Vaccines are Good ☺ Disease is Bad • Vaccines protect children and adults from 16 serious diseases and potential complications • There are record low rates of vaccine-preventable diseases And yet . We hear…….. Flu vaccine I don’t need a gave me the flu shot… Immunity flu! I never get the Flu vaccine from disease flu. doesn’t work. is better! Influenza is not a serious The side effects I’m pregnant illness. from a vaccine are so I can’t get worse than the vaccinated. Vaccines can disease! Vaccines make people Vaccines weaken your walk cause body's backwards. I am allergic Alzheimer's immune to eggs so I disease. can’t be response. vaccinated. Impact of Vaccines • The CDC estimates that vaccinations will prevent the following among children born in the last 20 years: ˗ 323 million illnesses ˗ 21 million hospitalizations ˗ 732,000 deaths • $295 billion in direct cost savings and $1.38 trillion in total societal costs CDC Media Brief Thursday April 24, 2014 Comparison of 20th Century Annual Morbidity and Current Morbidity: Vaccine-Preventable Diseases 20th Century 2016 Percent Disease Annual Morbidity† Reported Cases † † Decrease Smallpox 29,005 0 100% Diphtheria 21,053 0 100% Measles 530,217 69 > 99% Mumps 162,344 5,311 97% Pertussis 200,752 15,737 92% Polio (paralytic) 16,316 0 100% Rubella 47,745 5 > 99% Congenital Rubella Syndrome 152 1 99% Tetanus 580 33 94% Haemophilus influenzae 20,000 22* > 99% † JAMA.
    [Show full text]
  • AAP Immunizations Frequently Asked Questions: Evaluating Internet Information
    AAP Immunizations Frequently Asked Questions: Evaluating Internet Information With so many internet sites on childhood immunization or vaccines, how do I know which one is reliable? The Internet has made vast amounts of immunization resources available to the parents. Unfortunately, it is sometimes difficult to determine whether the information being presented is credible or not. In order to make an informed decision on the accuracy of immunization information obtained from the Internet, ask yourself the following questions: Who is providing this information? The source of the information (i.e., organization or individual) should be made clear, and more information about the source should be available. Be cautious of information attributed to unnamed sources. Is the information based on sound medical research? Scientific studies published in medical journals are reviewed by qualified professionals and are therefore credible sources. Information should contain references from and to peer-reviewed publications. Is the information up to date? Reliable sites show when they were last updated. Make sure the pages have been updated recently, and that the research cited is new. Does the information make sense? If you find information that is too good (or bad) to be true, it probably is. You should be able to follow up on the information through posted contact information. Additional reading lists should contain information from sources not directly linked to the site’s owner. Don’t assume that flawed information will be easy to detect. Always evaluate the credibility of material taken from the Internet. Remember, your child’s pediatrician is your best resource for immunization information – ask him/her to answer any questions you might have about information gathered from the Internet.
    [Show full text]